Identification

Name
Fludiazepam
Accession Number
DB01567
Type
Small Molecule
Groups
Approved, Illicit
Description

Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan.

Structure
Thumb
Synonyms
  • 7-chloro-5-(O-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
  • Erispan
  • Fludiazepamum
International/Other Brands
Erispan (Sumitomo)
Categories
UNII
7F64A2K16Z
CAS number
3900-31-0
Weight
Average: 302.731
Monoisotopic: 302.062218928
Chemical Formula
C16H12ClFN2O
InChI Key
ROYOYTLGDLIGBX-UHFFFAOYSA-N
InChI
InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
IUPAC Name
7-chloro-5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F

Pharmacology

Indication

Used for the short-term treatment of anxiety disorders.

Pharmacodynamics

Fludiazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Fludiazepam accumulates primarily in the cortex and thalamus.

Mechanism of action

Fludiazepam has similar action to diazepam, but binds with four times more affinity to benzodiazepine receptors than diazepam.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fludiazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fludiazepam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fludiazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amikacin.Approved, Investigational, Vet Approved
AminophyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fludiazepam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fludiazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fludiazepam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fludiazepam.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Azaperone.Investigational, Vet Approved
AzelastineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fludiazepam.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benperidol.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fludiazepam.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fludiazepam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fludiazepam.Approved, Investigational
BuprenorphineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fludiazepam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fludiazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fludiazepam.Approved, Illicit, Vet Approved
CaffeineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludiazepam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fludiazepam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fludiazepam.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fludiazepam.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fludiazepam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fludiazepam.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fludiazepam.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fludiazepam.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fludiazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fludiazepam.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fludiazepam.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fludiazepam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fludiazepam.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fludiazepam.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fludiazepam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fludiazepam.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fludiazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fludiazepam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fludiazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fludiazepam.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fludiazepam.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fludiazepam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fludiazepam.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fludiazepam.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fludiazepam.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fludiazepam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fludiazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fludiazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fludiazepam.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fludiazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fludiazepam.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fludiazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fludiazepam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fludiazepam.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fludiazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fludiazepam.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Fludiazepam.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fludiazepam is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fludiazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.Approved
DyphyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fludiazepam.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fludiazepam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fludiazepam.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fludiazepam.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Eperisone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fludiazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fludiazepam.Approved, Investigational
EthanolFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fludiazepam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fludiazepam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fludiazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fludiazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fludiazepam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Fludiazepam.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fludiazepam.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fludiazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fludiazepam.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fludiazepam.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluanisone.Experimental
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fludiazepam.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fludiazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fludiazepam.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fludiazepam.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fludiazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fludiazepam.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fludiazepam.Approved, Illicit, Investigational
GanciclovirThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ganciclovir.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fludiazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fludiazepam.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fludiazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fludiazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fludiazepam.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fludiazepam.Approved
HyaluronidaseThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fludiazepam.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fludiazepam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indiplon.Investigational
IsocarboxazidThe therapeutic efficacy of Fludiazepam can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fludiazepam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fludiazepam.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fludiazepam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fludiazepam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fludiazepam.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fludiazepam.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fludiazepam.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fludiazepam.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Fludiazepam can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fludiazepam.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fludiazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Fludiazepam can be increased when it is combined with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fludiazepam.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fludiazepam.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Fludiazepam can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fludiazepam.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fludiazepam.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fludiazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fludiazepam.Approved
MethadoneFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fludiazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fludiazepam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fludiazepam.Approved
MethotrimeprazineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fludiazepam.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fludiazepam.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fludiazepam.Approved
MetyrosineFludiazepam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Investigational
MirtazapineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fludiazepam.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Neomycin.Approved, Vet Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fludiazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fludiazepam.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fludiazepam.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludiazepam.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fludiazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Fludiazepam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fludiazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fludiazepam.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fludiazepam.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam.Approved
ParaldehydeFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fludiazepam.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fludiazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fludiazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fludiazepam.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fludiazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fludiazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fludiazepam.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fludiazepam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fludiazepam.Approved
PramipexoleFludiazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Fludiazepam can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fludiazepam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fludiazepam.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fludiazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fludiazepam.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fludiazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fludiazepam.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Fludiazepam is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fludiazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fludiazepam.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fludiazepam.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Rizatriptan.Approved
RomifidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Romifidine.Vet Approved
RopiniroleFludiazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam.Approved
RotigotineFludiazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fludiazepam.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fludiazepam.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam.Approved, Vet Approved
Sodium oxybateFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Fludiazepam.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sumatriptan.Approved, Investigational
SuvorexantFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fludiazepam.Approved, Investigational
TeduglutideThe serum concentration of Fludiazepam can be increased when it is combined with Teduglutide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fludiazepam.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fludiazepam.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrodotoxin.Investigational
ThalidomideFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fludiazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fludiazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fludiazepam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fludiazepam.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fludiazepam.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fludiazepam.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fludiazepam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fludiazepam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fludiazepam.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fludiazepam.Approved
ValaciclovirThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Valaciclovir.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fludiazepam.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fludiazepam.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fludiazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fludiazepam.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zolmitriptan.Approved, Investigational
ZolpidemFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fludiazepam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fludiazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fludiazepam.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.

References

Synthesis Reference

Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.

General References
  1. Ishiwata K, Yanai K, Ido T, Miura-Kanno Y, Kawashima K: Synthesis and biodistribution of [11C]fludiazepam for imaging benzodiazepine receptors. Int J Rad Appl Instrum B. 1988;15(4):365-71. [PubMed:2855634]
  2. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
External Links
Human Metabolome Database
HMDB0015513
KEGG Drug
D01354
PubChem Compound
3369
PubChem Substance
46507563
ChemSpider
3252
ChEBI
31618
ChEMBL
CHEMBL13291
Therapeutic Targets Database
DAP000934
PharmGKB
PA164745609
Wikipedia
Fludiazepam
ATC Codes
N05BA17 — Fludiazepam

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)218.5-219Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.
logP2.75HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP2.83ALOGPS
logP3.22ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)1.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity80.03 m3·mol-1ChemAxon
Polarizability29.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9946
Caco-2 permeable+0.8567
P-glycoprotein substrateSubstrate0.6618
P-glycoprotein inhibitor IInhibitor0.5293
P-glycoprotein inhibitor IINon-inhibitor0.8532
Renal organic cation transporterInhibitor0.592
CYP450 2C9 substrateNon-substrate0.6724
CYP450 2D6 substrateNon-substrate0.9087
CYP450 3A4 substrateSubstrate0.8081
CYP450 1A2 substrateInhibitor0.7925
CYP450 2C9 inhibitorNon-inhibitor0.5446
CYP450 2D6 inhibitorNon-inhibitor0.8884
CYP450 2C19 inhibitorInhibitor0.5598
CYP450 3A4 inhibitorInhibitor0.5153
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5827
Ames testNon AMES toxic0.8792
CarcinogenicityNon-carcinogens0.817
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9953
hERG inhibition (predictor II)Non-inhibitor0.8236
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0uk9-2794000000-6f1a3e2e0783b2069f2f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Fluorobenzenes / Aryl fluorides / Aryl chlorides / Tertiary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds
show 5 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, organochlorine compound, 1,4-benzodiazepinone (CHEBI:31618)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046]

Drug created on July 31, 2007 07:10 / Updated on August 02, 2018 04:38